 This study is being conducted to evaluate the safety and effectiveness of lenalidomide Revlimid in subjects with Cutaneous Lupus Erythematosus CLE. The study drug will be used in an off-label indication to treat 6 subjects for 12 months each. Men and women over the age of 18, who have a biopsy proven diagnosis of CLE and who have failed standard treatment, will be included in the study. 